Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the ...

Amycretin, an oral weight loss pill developed by the makers of Wegovy, led to a 13.1% weight loss over three months in early ...

Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Eli Lilly and Company ’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...

A daily diet pill has shown promising results in early trials, with participants losing an average of 13% of their body ...

As retail investors flock to Viking Therapeutics, the biotech firm is also catching the eye of billionaire fund managers like ...

The treatment of sleep disorders in India has evolved significantly over the years, transitioning from basic lifestyle advice ...

Weight-loss jabs Ozempic and Wegovy have been touted as miracle jabs revolutionizing how obesity is treated. Now the maker of these drugs is touting a new weight-loss pill that is said to help obese ...